A new method has been devised to produce generic chimeric antigen receptor (CAR) T cells at scale by directing induced pluripotent stem cells (iPSCs) to differentiate into mature T cells in vitro. The generic T cells can then be engineered to express a range of different chimeric antigen receptors. Read More
In a recent study, researchers from Shanghai Jiao Tong University in China investigated the epigenetic program responsible for cartilage injury induced by aberrant mechanical force, with the final aim of exploring a potential epigenetic-based therapy approach for osteoarthritis. Read More
With the aim of assessing the implication of gap junction protein connexin 43 (Cx43) in angiogenesis, human pulmonary microvascular endothelial cells were transfected with Cx43-targeting siRNA or Cx43-overexpressing recombinant plasmid vector. Read More
Shanghai Shengdi Pharmaceutical, Shanghai Senhui Pharmaceutical and Jiangsu Hengrun Pharmaceutical have divulged new cephems (cephalosporins) reported to be useful for the treatment of Gram-negative bacterial infections. Read More
Shenzhen Chipscreen Biosciences and Chengdu Chipscreen Pharmaceutical have presented new ATR kinase inhibitors reported to be useful for the treatment of cancer. Read More
The National Institute of Pharmaceutical R&D (Beijing) has identified condensed heterocyclic compounds acting as insulin secretagogues and gluconeogenesis inhibitors reported to be useful for the treatment of diabetes. Read More
Anticancer Bioscience and the J Michael Bishop Institute of Cancer Research have described fused azepine compounds reported to be useful for the treatment of cancer. Read More
A radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI) has shown that intravenous administration of Athersys' MultiStem (invimestrocel) provided benefit in an animal model of acute radiation syndrome (ARS). Read More
Mersana Therapeutics has entered into an option agreement with GSK for the codevelopment and commercialization of XMT-2056, an Immunosynthen antibody-drug conjugate (ADC) that targets a novel epitope of HER2. Read More
Infex Therapeutics has been awarded a grant of GBP 850,000 by Innovate UK Biomedical Catalyst to support its 18-month COV-X project, currently in the preclinical phase, on the optimization of a novel series of SARS-CoV-2 inhibitors. Read More
SymBio Pharmaceuticals has entered into a collaboration agreement with the National Institute of Neurological Disorders and Stroke (NINDS) on the evaluation of brincidofovir's potential antiviral effect on Epstein Barr virus (EBV). Read More
HDT Bio has been awarded a nearly USD 1.8 million grant from the U.S. Army Medical Research Acquisition Activity to develop HDT-201 into an antiviral intranasal spray that can stimulate the body's innate immune system to treat and prevent a broad spectrum of deadly human viruses. Read More
